Nektar Therapeutics has unveiled updated results from a Phase Ib trial of its atopic dermatitis (AD) candidate, rezpegaldesleukin, in the midst of a case against ex-partner Eli Lilly.

在针对前合作伙伴Eli Lilly的案例中，Nektar Therapeutics公布了其特应性皮炎（AD）候选人rezpegaldesleukin的Ib期临床试验的最新结果。

High-dose rezpegaldesleukin produced a mean 72% improvement in affected body surface area at 12 weeks versus placebo’s 36% (p=0.00158). The drug also saw a mean 78% improvement in the dermatology life quality index and a 58% improvement in the patient-oriented eczema measure.

高剂量rezpegaldesleukin在12周时使受影响的体表面积平均改善72%，而安慰剂组为36%（p=0.00158）。该药物的皮肤病生活质量指数平均改善78%，改善58%以患者为导向的湿疹措施。

Unlock this article instantly by becoming a free subscriber.

成为免费用户立即解锁本文。

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

您可以每月访问免费文章，还可以自定义每周发送到框中的新闻通讯，包括新闻报道。

SIGN UP

注册

LOG IN

登录

BECOME A PREMIUM SUBSCRIBER

成为高级用户